Recent News

• 03.31.2025 - Rani Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call
• 03.31.2025 - Rani Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call
• 03.31.2025 - Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
• 03.31.2025 - Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
• 03.26.2025 - Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
• 03.26.2025 - Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
• 03.25.2025 - Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
• 03.25.2025 - Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
• 02.05.2025 - Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
• 02.05.2025 - Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

Recent Filings

• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - 8-K Current report
• 03.31.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.31.2025 - EX-99.1 EX-99.1
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities